We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx®-265
News

Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx®-265

Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx®-265
News

Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx®-265

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx®-265"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Therapeutics Corp. has announced that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,846,898- entitled, "Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis."

The claims cover the use of luteinizing hormone (LH) or human chorionic gonadotrophin (hCG) and erythropotein (EPO) for producing neural stem cells (in vitro & in vivo), which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells.

The covered in vivo uses include administration of these compounds to subjects having neurodegenerative conditions, diseases and CNS injuries. This is the first U.S. patent to issue in this patent family and it protects the use of the NTx®-265 regimen in the acute neurologic injury indications of Stroke, and Traumatic Brain Injury, amongst other indications.

Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "We at SCT are very excited to see this patent issue as it represents an important intellectual property milestone for the NTx®-265 program. This patent offers protection and support for our NTx®-265 technology, a keystone patent, while expanding and increasing value to SCT's overall intellectual property portfolio."
Advertisement